Clinical DevelopmentLast reviewed May 2026

Clinical Hold(Clinical Hold)

An FDA order to a sponsor to delay a proposed or suspend an ongoing clinical investigation due to safety concerns or deficiencies.

Usage Examples

FDA placed the Phase 1 trial on partial clinical hold pending additional nonclinical toxicology.
The sponsor responded to the hold with updated dose escalation safety monitoring plans.
FDA lifted the clinical hold four weeks after the Complete Response was submitted.

What is Clinical Hold?

A clinical hold is an FDA directive requiring a sponsor to delay initiation of a proposed trial or suspend an ongoing trial conducted under an IND. FDA places trials on clinical hold when it identifies significant concerns — most commonly safety issues, inadequate risk-benefit justification, investigator qualifications, or informed consent deficiencies under 21 CFR 312.42.

A full clinical hold prevents any dosing of human subjects in the trial. A partial clinical hold restricts specific aspects — a particular dose level, patient population, or protocol element — while allowing other activities to continue. FDA communicates the hold with the specific deficiencies the sponsor must address. Sponsors respond with a Complete Response Letter addressing the hold issues, after which FDA lifts the hold once satisfied.

Clinical holds affect program timelines significantly. A single hold can delay a trial by weeks to months depending on the complexity of the issues and response development. Multiple or recurring holds signal broader program weaknesses that can affect FDA's view of the sponsor's development strategy. Sponsors typically work closely with FDA during the response period to ensure the resolution adequately addresses the cited concerns.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312 42, FDCA.

FDAEMAPMDA

When This Matters

FDA placed the Phase 1 trial on partial clinical hold pending additional nonclinical toxicology.
The sponsor responded to the hold with updated dose escalation safety monitoring plans.
FDA lifted the clinical hold four weeks after the Complete Response was submitted.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

21 CFR 312 42FDCA

How to Respond to an FDA Clinical Hold

Develop and submit a Complete Response to FDA that addresses clinical hold deficiencies and lifts the hold.

1
Receive and analyze the hold letter
FDA's hold letter lists specific deficiencies. Parse each cited issue carefully — some require new data (additional nonclinical studies), some require analysis (expanded safety review), some require protocol changes (revised monitoring, different dose).
2
Engage FDA if clarification is needed
If deficiencies are ambiguous, request a Type A meeting with FDA within 30 days. Type A meetings are scheduled fast (within 30 days) specifically for clinical hold discussions.
3
Develop corrective actions
For each cited deficiency, identify the specific remediation: new toxicology studies, updated nonclinical summary, protocol amendment, revised consent form, new safety monitoring plan, or updated Investigator's Brochure.
4
Execute additional studies if needed
Nonclinical toxicology extensions or additional studies may take months. Start these in parallel with other response activities to minimize program delay.
5
Compile the Complete Response
Organize the response as an IND amendment addressing each deficiency in the order FDA cited them. Include cross-references to supporting data, updated protocol documents, and revised IB sections.
6
Submit and track
Submit the Complete Response through the IND. FDA has 30 days to respond with lift, partial lift, or additional concerns. Track the response outcome and close associated tasks in the sponsor's regulatory system.

Frequently Asked Questions

Common triggers include unreasonable risk of serious harm, investigators qualifications, inadequate informed consent, protocol that clearly fails to meet stated objectives, incomplete IND, or a serious safety signal emerging during an ongoing trial. 21 CFR 312.42 codifies the specific grounds.

Varies significantly. Simple resolutions (administrative corrections, updated consent language) can be lifted in weeks. Complex safety-driven holds involving new nonclinical studies or protocol redesign can take months to resolve. FDA responds to hold resolution submissions within 30 days.

Full hold prevents any human subject dosing in the affected trial. Partial hold restricts specific activities — e.g., a particular dose level, a specific patient population, or a protocol element — while allowing other trial activities to continue under the IND.